Log in
RegisterFDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]
Hi all,
The FDA just posted a draft guidance on Good ANDA submission practices:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf
I found the section on deviations from product-specific guidances to be rather interesting such as:
A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.
So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?
BRB
The FDA just posted a draft guidance on Good ANDA submission practices:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf
I found the section on deviations from product-specific guidances to be rather interesting such as:
A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.
So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?
BRB
Complete thread:
- FDA Draft guidance on Good ANDA Submission PracticesBRB 2018-01-03 21:42
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
Ing. Helmut Schütz